Is there a role for mitomycin C in metastatic colorectal cancer?
- 30 April 2010
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 19 (6), 723-735
- https://doi.org/10.1517/13543784.2010.485191
Abstract
Fluoropyrimidines with oxaliplatin or irinotecan, bevacizumab, cetuximab and panitumumab constitute the drugs currently approved by the FDA for the treatment of patients with metastatic colorectal cancer (mCRC). Patients who have progressed on the approved drugs pose a major challenge for medical oncologists, as the therapeutic choices outside the context of a clinical trial are limited. Mitomycin C is an old drug that acts synergistically with capecitabine and irinotecan. Relevant studies were identified in PubMed (years 1950 - 2009), Ovid, Cochrane database and the American Society of Clinical Oncology abstracts (years 1995 - 2009) using the following search terms: mitomycin C, fluorouracil, capecitabine, irinotecan, oxaliplatin, and colorectal cancer. Only studies using the combination of mitomycin C with one of the aforementioned agents were selected. An overview of the clinical trials where mitomycin has been used in combination with modern compounds in the various settings of metastatic colorectal cancer. Mitomycin C combinations are less efficacious than modern drugs in the first-line treatment of colorectal cancer. However, they are acceptable alternatives for best supportive care in colorectal cancer that is refractory to standard regimens, as they show some modest efficacy at low cost.Keywords
This publication has 36 references indexed in Scilit:
- Therapeutic options in the management of intermediate‐risk nonmuscle‐invasive bladder cancerBJU International, 2009
- Mitomycin plus vinorelbine salvage chemotherapy in non-small cell lung cancer: A prospective studyLung Cancer, 2008
- Capecitabine and Mitomycin C Is an Effective Combination for Anthracycline- and Taxane-Resistant Metastatic Breast CancerOncology, 2006
- Irinotecan and Mitomycin C in 5-Fluorouracil-Refractory Colorectal Cancer PatientsOncology, 2001
- Modulation of DNA Topoisomerase I Activity by p53Biochemistry, 1996
- Effects of CPT‐11 in combination with other anti‐cancer agents in cultureInternational Journal of Cancer, 1992
- Mechanism of monofunctional and bifunctional alkylation of DNA by mitomycin CBiochemistry, 1988
- Bioactivation as a Model for Drug Design Bioreductive AlkylationScience, 1977
- Mitomycins and Porfiromycin: Chemical Mechanism of Activation and Cross-linking of DNAScience, 1964
- Mitomycin C: Chemical and Biological Studies on AlkylationScience, 1963